Visterra Licenses Dengue IP From MIT, Tops Off Series A To $34.2 Million
This article was originally published in The Pink Sheet Daily
The biotech plans to file an IND for its lead antibody candidate in seasonal and pandemic flu in early 2014. It also will optimize MIT research into dengue virus to find a clinical candidate to treat dengue fever.
You may also be interested in...
To help push an antibody flu treatment into the clinic, the biotech has added $13 million from The Gates Foundation and others to bring total Series A funding to $26 million.
Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.
The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.